VolitionRx Limited Issues Mid-Year Review Ahead of 2024 Annual Meeting

Stock Information for VolitionRX Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About VolitionRX Limited

VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update
VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update
VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption
VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets
VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update
Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025
Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025
VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.